AbbVie

Leadership transition appears well planned. Robert A. Michael, a seasoned AbbVie executive, became CEO on July 1, 2024 and was elected Chairman effective July 1, 2025, with Rick Gonzalez moving to and later retiring from the board.

The team executed through the Humira cliff and pivoted capital to the next growth engines while sustaining high returns and cash generation. Messaging and guidance discipline were evident with a Q1 2025 guidance raise and an October 2025 update reflecting a large IPR&D charge. Governance shows continuity with a focus on pipeline depth and BD.

Jurisdictional risk is low with U.S. domicile, broad global operations, and no VIE structures.

Sources: AbbVie CEO transition releases; Reuters guidance update Oct 3, 2025. Quality Value Investing Checklist (scores and brief rationale): Wide or Narrow Moat (Morningstar): 90. Morningstar rates AbbVie wide; we concur given immunology leadership, Botox brand, and IP. Source: Morningstar; our analysis.

High and Consistent Return on Capital: 75. ROIC around low double digits TTM despite heavy intangibles; strong FCF returns. Source: 10-K; Gurufocus snapshot. Revenue and FCF Growth: 75. Multi-year revenue stabilizing post-Humira with high-teens growth in next-gen assets; TTM FCF ~18.2 billion dollars. Source: 10-Q; 10-K.

High Margins: 85. Gross margin ~70 to 72 percent; adjusted operating margins strong; FCF margin ~31 percent TTM. Source: 10-Q; 10-K. Owner-CEO: 70. Founder-like stewardship has transitioned; CEO is long-tenured insider with aligned incentives. Source: AbbVie releases.

Simplicity: 65. Multi-therapy pharma adds complexity and trial/policy risk vs pure tollbooths. Very Low Debt: 45. Net debt ~64 billion dollars; coverage solid but leverage is material. Source: 10-Q. Dilution: 75. SBC moderate; share count stable to slightly down with buybacks. Source: 10-K; 10-Q.

Favorable Jurisdiction: 90. U.S.-based, global operations, no VIE. Policy risk from IRA acknowledged. Source: CMS. Trend Alignment & Boringness: 80. Autoimmune, neuroscience, oncology tailwinds; aesthetics cyclical but enduring brand. Source: 10-Q; Q1 release.

Superinvestor Inspiration: 70. Classic high-cash-flow pharma profile with durable assets; favored by quality-value frameworks. Valuation: 60. On our FCF-based lens, the business quality is high but requires price discipline for attractive forward returns.